Cutaneous and Systemic Leishmaniasis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global Cutaneous and Systemic Leishmaniasis market is on an upward trajectory over the forecast period 2024-2031. This growth can be attributed to several key factors that are driving the market's expansion.
High Clinical Cure Rate with Combinational Drug Therapy
One of the pivotal factors fueling the growth of the Cutaneous and Systemic Leishmaniasis market is the impressive clinical cure rate achieved through combinational drug therapy. The use of various drug combinations has proven to be highly effective, with some combinations even resulting in complete cures. This promising aspect is expected to sustain the market's growth throughout the forecast period.
Increased Investments for Research And Development
Numerous stakeholders in the Cutaneous and Systemic Leishmaniasis market are making substantial investments in research and development efforts aimed at developing innovative treatment alternatives. Ongoing clinical trials for a wide range of drugs and therapies show promising outcomes, which are anticipated to open up new opportunities for treating cutaneous and systemic leishmaniasis.
Favorable Reimbursement Policies
Governments worldwide are significantly investing in healthcare infrastructure, contributing to the growth of the market. Additionally, private health insurance providers are offering favorable reimbursement policies, allowing patients to choose plans that best suit their needs, further facilitating access to treatment.
However, the market does face some challenges:
High Cost of Treatment and Chances Of Side Effects
The cost of treating Cutaneous and Systemic Leishmaniasis remains relatively high due to expensive drugs, and these treatments may have serious side effects. Nevertheless, ongoing research and development efforts are expected to yield more cost-effective and safer treatment options in the future.
Impact of COVID-19
The COVID-19 pandemic initially led to a decrease in demand for Cutaneous & Systemic Leishmaniasis treatment due to healthcare facilities' overwhelming focus on managing the pandemic. However, as the situation improved in 2021, demand for these treatments started to rebound.
Competitive Analysis
The Cutaneous and Systemic Leishmaniasis market is fiercely competitive and is characterized by major players dominating the industry. Market participants are embracing new and innovative strategies, including technological collaborations, distributorship agreements, increased research and development, and product launches, to meet growing demand and establish their dominance in regional markets.
Key Companies Profiled
• Gilead Sciences, Inc.
• Profounda Pharmaceuticals
• Knight Therapeutics Inc.
• Janssen Global Services, LLC
• Albert David Ltd
• Jubilant Life Sciences Ltd.
• Novartis AG
• Sanofi
• Endo Pharmaceuticals Inc
• Bristol-Myers Squibb Company
• United Biotech Pvt. Ltd.
As the Cutaneous & Systemic Leishmaniasis market continues to grow and evolve, these key players are at the forefront of driving advancements in research, development, and access to treatment, ensuring a brighter future for those affected by this disease.
Cutaneous and Systemic Leishmaniasis Market Categorization
Cutaneous and Systemic Leishmaniasis Market by By Drug Class
• Pentavalent Antimonials
• Antifungal Drugs
• Anti-Lesihmanial/Antimicrobial Drugs
Cutaneous and Systemic Leishmaniasis Market By Route of Administration
• Oral
• Injectable
• Topical
Cutaneous and Systemic Leishmaniasis Market By Indication
• Cutaneous Leishmaniasis
• Mucosal Leishmaniasis
• Visceral Leishmaniasis
Cutaneous and Systemic Leishmaniasis Market By Distribution Channel
• Hospital Pharmacies,
• Retail Pharmacies
• Drug Stores
• Online Pharmacies
Cutaneous and Systemic Leishmaniasis Market by Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.
- 1. Executive Summary
- 1.1. Global Cutaneous and Systemic Leishmaniasis Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2023
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. Porter’s Five Forces Analysis
- 2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
- 2.6. Impact of Ukraine-Russia Conflict
- 2.7. Economic Overview
- 2.7.1. World Economic Projections
- 2.8. PESTLE Analysis
- 3. Global Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 – 2031
- 3.1. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 – 2031
- 3.1.1. Key Highlights
- 3.1.1.1. Pentavalent Antimonials
- 3.1.1.2. Antifungal Drugs
- 3.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
- 3.2. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
- 3.2.1. Key Highlights
- 3.2.1.1. Oral
- 3.2.1.2. Injectable
- 3.2.1.3. Topical
- 3.3. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
- 3.3.1. Key Highlights
- 3.3.1.1. Cutaneous Leishmaniasis
- 3.3.1.2. Mucosal Leishmaniasis
- 3.3.1.3. Visceral Leishmaniasis
- 3.4. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 3.4.1. Key Highlights
- 3.4.1.1. Hospital Pharmacies,
- 3.4.1.2. Retail Pharmacies
- 3.4.1.3. Drug Stores
- 3.4.1.4. Online Pharmacies
- 3.5. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
- 3.5.1. Key Highlights
- 3.5.1.1. North America
- 3.5.1.2. Europe
- 3.5.1.3. Asia Pacific
- 3.5.1.4. Latin America
- 3.5.1.5. Middle East & Africa
- 4. North America Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 – 2031
- 4.1. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 – 2031
- 4.1.1. Key Highlights
- 4.1.1.1. Pentavalent Antimonials
- 4.1.1.2. Antifungal Drugs
- 4.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
- 4.2. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
- 4.2.1. Key Highlights
- 4.2.1.1. Oral
- 4.2.1.2. Injectable
- 4.2.1.3. Topical
- 4.3. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
- 4.3.1. Key Highlights
- 4.3.1.1. Cutaneous Leishmaniasis
- 4.3.1.2. Mucosal Leishmaniasis
- 4.3.1.3. Visceral Leishmaniasis
- 4.4. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 4.4.1. Key Highlights
- 4.4.1.1. Hospital Pharmacies,
- 4.4.1.2. Retail Pharmacies
- 4.4.1.3. Drug Stores
- 4.4.1.4. Online Pharmacies
- 4.4.2. BPS Analysis/Market Attractiveness Analysis
- 4.5. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 4.5.1. Key Highlights
- 4.5.1.1. U.S. Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 4.5.1.2. U.S. Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 4.5.1.3. U.S. Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 4.5.1.4. U.S. Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 4.5.1.5. Canada Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 4.5.1.6. Canada Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 4.5.1.7. Canada Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 4.5.1.8. Canada Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 4.5.2. BPS Analysis/Market Attractiveness Analysis
- 5. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 – 2031
- 5.1. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 – 2031
- 5.1.1. Key Highlights
- 5.1.1.1. Pentavalent Antimonials
- 5.1.1.2. Antifungal Drugs
- 5.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
- 5.2. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
- 5.2.1. Key Highlights
- 5.2.1.1. Oral
- 5.2.1.2. Injectable
- 5.2.1.3. Topical
- 5.3. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
- 5.3.1. Key Highlights
- 5.3.1.1. Cutaneous Leishmaniasis
- 5.3.1.2. Mucosal Leishmaniasis
- 5.3.1.3. Visceral Leishmaniasis
- 5.4. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1. Key Highlights
- 5.4.1.1. Hospital Pharmacies,
- 5.4.1.2. Retail Pharmacies
- 5.4.1.3. Drug Stores
- 5.4.1.4. Online Pharmacies
- 5.4.2. BPS Analysis/Market Attractiveness Analysis
- 5.5. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 5.5.1. Key Highlights
- 5.5.1.1. Germany Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 5.5.1.2. Germany Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 5.5.1.3. Germany Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.4. Germany Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.1.5. U.K. Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 5.5.1.6. U.K. Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 5.5.1.7. U.K. Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.8. U.K. Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.1.9. France Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 5.5.1.10. France Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 5.5.1.11. France Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.12. France Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.1.13. Italy Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 5.5.1.14. Italy Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 5.5.1.15. Italy Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.16. Italy Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.1.17. Turkey Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 5.5.1.18. Turkey Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 5.5.1.19. Turkey Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.20. Turkey Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.1.21. Russia Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 5.5.1.22. Russia Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 5.5.1.23. Russia Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.24. Russia Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.1.25. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 5.5.1.26. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 5.5.1.27. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.5.1.28. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.5.2. BPS Analysis/Market Attractiveness Analysis
- 6. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 – 2031
- 6.1. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 – 2031
- 6.1.1. Key Highlights
- 6.1.1.1. Pentavalent Antimonials
- 6.1.1.2. Antifungal Drugs
- 6.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
- 6.2. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
- 6.2.1. Key Highlights
- 6.2.1.1. Oral
- 6.2.1.2. Injectable
- 6.2.1.3. Topical
- 6.3. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
- 6.3.1. Key Highlights
- 6.3.1.1. Cutaneous Leishmaniasis
- 6.3.1.2. Mucosal Leishmaniasis
- 6.3.1.3. Visceral Leishmaniasis
- 6.4. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.4.1. Key Highlights
- 6.4.1.1. Hospital Pharmacies,
- 6.4.1.2. Retail Pharmacies
- 6.4.1.3. Drug Stores
- 6.4.1.4. Online Pharmacies
- 6.4.2. BPS Analysis/Market Attractiveness Analysis
- 6.5. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 6.5.1. Key Highlights
- 6.5.1.1. China Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 6.5.1.2. China Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 6.5.1.3. China Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 6.5.1.4. China Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.5.1.5. Japan Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 6.5.1.6. Japan Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 6.5.1.7. Japan Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 6.5.1.8. Japan Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.5.1.9. South Korea Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 6.5.1.10. South Korea Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 6.5.1.11. South Korea Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 6.5.1.12. South Korea Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.5.1.13. India Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 6.5.1.14. India Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 6.5.1.15. India Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 6.5.1.16. India Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.5.1.17. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 6.5.1.18. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 6.5.1.19. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 6.5.1.20. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.5.1.21. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 6.5.1.22. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 6.5.1.23. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 6.5.1.24. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.5.2. BPS Analysis/Market Attractiveness Analysis
- 7. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 – 2031
- 7.1. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 – 2031
- 7.1.1. Key Highlights
- 7.1.1.1. Pentavalent Antimonials
- 7.1.1.2. Antifungal Drugs
- 7.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
- 7.2. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
- 7.2.1. Key Highlights
- 7.2.1.1. Oral
- 7.2.1.2. Injectable
- 7.2.1.3. Topical
- 7.3. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
- 7.3.1. Key Highlights
- 7.3.1.1. Cutaneous Leishmaniasis
- 7.3.1.2. Mucosal Leishmaniasis
- 7.3.1.3. Visceral Leishmaniasis
- 7.4. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.4.1. Key Highlights
- 7.4.1.1. Hospital Pharmacies,
- 7.4.1.2. Retail Pharmacies
- 7.4.1.3. Drug Stores
- 7.4.1.4. Online Pharmacies
- 7.4.2. BPS Analysis/Market Attractiveness Analysis
- 7.5. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 7.5.1. Key Highlights
- 7.5.1.1. Brazil Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 7.5.1.2. Brazil Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 7.5.1.3. Brazil Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 7.5.1.4. Brazil Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.5.1.5. Mexico Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 7.5.1.6. Mexico Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 7.5.1.7. Mexico Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 7.5.1.8. Mexico Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.5.1.9. Argentina Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 7.5.1.10. Argentina Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 7.5.1.11. Argentina Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 7.5.1.12. Argentina Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.5.1.13. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 7.5.1.14. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 7.5.1.15. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 7.5.1.16. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.5.2. BPS Analysis/Market Attractiveness Analysis
- 8. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 – 2031
- 8.1. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 – 2031
- 8.1.1. Key Highlights
- 8.1.1.1. Pentavalent Antimonials
- 8.1.1.2. Antifungal Drugs
- 8.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
- 8.2. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
- 8.2.1. Key Highlights
- 8.2.1.1. Oral
- 8.2.1.2. Injectable
- 8.2.1.3. Topical
- 8.3. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
- 8.3.1. Key Highlights
- 8.3.1.1. Cutaneous Leishmaniasis
- 8.3.1.2. Mucosal Leishmaniasis
- 8.3.1.3. Visceral Leishmaniasis
- 8.4. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.4.1. Key Highlights
- 8.4.1.1. Hospital Pharmacies,
- 8.4.1.2. Retail Pharmacies
- 8.4.1.3. Drug Stores
- 8.4.1.4. Online Pharmacies
- 8.4.2. BPS Analysis/Market Attractiveness Analysis
- 8.5. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 8.5.1. Key Highlights
- 8.5.1.1. GCC Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 8.5.1.2. GCC Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 8.5.1.3. GCC Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 8.5.1.4. GCC Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.5.1.5. South Africa Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 8.5.1.6. South Africa Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 8.5.1.7. South Africa Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 8.5.1.8. South Africa Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.5.1.9. Egypt Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 8.5.1.10. Egypt Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 8.5.1.11. Egypt Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 8.5.1.12. Egypt Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.5.1.13. Nigeria Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 8.5.1.14. Nigeria Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 8.5.1.15. Nigeria Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 8.5.1.16. Nigeria Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.5.1.17. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 – 2031
- 8.5.1.18. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 – 2031
- 8.5.1.19. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 – 2031
- 8.5.1.20. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.5.2. BPS Analysis/Market Attractiveness Analysis
- 9. Competitive Landscape
- 9.1. Drug Class vs Indication Heatmap
- 9.2. Company Market Share Analysis, 2023
- 9.3. Competitive Dashboard
- 9.4. Company Profiles
- 9.4.1. Gilead Sciences, Inc.
- 9.4.1.1. Company Overview
- 9.4.1.2. Product Portfolio
- 9.4.1.3. Financial Overview
- 9.4.1.4. Business Strategies and Development
- 9.4.2. Profounda Pharmaceuticals
- 9.4.2.1. Company Overview
- 9.4.2.2. Product Portfolio
- 9.4.2.3. Financial Overview
- 9.4.2.4. Business Strategies and Development
- 9.4.3. Knight Therapeutics Inc.
- 9.4.3.1. Company Overview
- 9.4.3.2. Product Portfolio
- 9.4.3.3. Financial Overview
- 9.4.3.4. Business Strategies and Development
- 9.4.4. Janssen Global Services, LLC
- 9.4.4.1. Company Overview
- 9.4.4.2. Product Portfolio
- 9.4.4.3. Financial Overview
- 9.4.4.4. Business Strategies and Development
- 9.4.5. Albert David Ltd
- 9.4.5.1. Company Overview
- 9.4.5.2. Product Portfolio
- 9.4.5.3. Financial Overview
- 9.4.5.4. Business Strategies and Development
- 9.4.6. Jubilant Life Sciences Ltd.
- 9.4.6.1. Company Overview
- 9.4.6.2. Product Portfolio
- 9.4.6.3. Financial Overview
- 9.4.6.4. Business Strategies and Development
- 9.4.7. Novartis AG
- 9.4.7.1. Company Overview
- 9.4.7.2. Product Portfolio
- 9.4.7.3. Financial Overview
- 9.4.7.4. Business Strategies and Development
- 9.4.8. Sanofi
- 9.4.8.1. Company Overview
- 9.4.8.2. Product Portfolio
- 9.4.8.3. Financial Overview
- 9.4.8.4. Business Strategies and Development
- 9.4.9. Endo Pharmaceuticals Inc
- 9.4.9.1. Company Overview
- 9.4.9.2. Product Portfolio
- 9.4.9.3. Financial Overview
- 9.4.9.4. Business Strategies and Development
- 9.4.10. Bristol-Myers Squibb Company
- 9.4.10.1. Company Overview
- 9.4.10.2. Product Portfolio
- 9.4.10.3. Financial Overview
- 9.4.10.4. Business Strategies and Development
- 9.4.11. United Biotech Pvt. Ltd.
- 9.4.11.1. Company Overview
- 9.4.11.2. Product Portfolio
- 9.4.11.3. Financial Overview
- 9.4.11.4. Business Strategies and Development
- 10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook